Healthcare [ 11/13 ] | Drug Manufacturers - General [ 96/159 ]
NYSE | Common Stock
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally.
The company offers prescription medicines for patients and physicians.
It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.
Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria.
The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Apr 23, 24 | 1.8 Increased by +5.26% | 1.67 Increased by +7.78% |
| Jan 31, 24 | 1.53 Increased by +0.66% | 1.69 Decreased by -9.47% |
| Oct 24, 23 | 1.83 Increased by +15.82% | 1.7 Increased by +7.65% |
| Jul 19, 23 | 1.83 Increased by +17.31% | 1.68 Increased by +8.93% |
| Apr 25, 23 | 1.71 Increased by +17.12% | 1.55 Increased by +10.32% |
| Feb 1, 23 | 1.52 Increased by +8.57% | 1.44 Increased by +5.56% |
| Oct 25, 22 | 1.58 Decreased by -7.6% | 1.55 Increased by +1.94% |
| Jul 19, 22 | 1.56 Decreased by -6.02% | 1.5 Increased by +4% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 23 | 11.78 B Decreased by -10.02% | 8.48 B Increased by +478.44% | Increased by +72.01% Increased by +542.84% |
| Sep 30, 23 | 12.09 B Decreased by -5.84% | 1.76 B Increased by +11.95% | Increased by +14.56% Increased by +18.9% |
| Jun 30, 23 | 13.94 B Increased by +6.5% | 2.32 B Increased by +36.72% | Increased by +16.62% Increased by +28.37% |
| Mar 31, 23 | 13.21 B Increased by +3.07% | 2.29 B Increased by +3.2% | Increased by +17.36% Increased by +0.12% |
| Dec 31, 22 | 13.09 B Decreased by -3.22% | 1.47 B Decreased by -91.01% | Increased by +11.2% Decreased by -90.71% |
| Sep 30, 22 | 12.84 B Decreased by -3.93% | 1.57 B Decreased by -42.97% | Increased by +12.25% Decreased by -40.63% |
| Jun 30, 22 | 13.09 B Decreased by -1.57% | 1.69 B Decreased by -41.51% | Increased by +12.95% Decreased by -40.57% |
| Mar 31, 22 | 12.81 B Increased by +0.95% | 2.22 B Increased by +7.92% | Increased by +17.34% Increased by +6.91% |